Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-08-25

Clinical Trial Update: Multiple Dose BE Study With Nevirapine 400mg PR Tablets [Phase 1]

View source ↗

Summary

Phase 1 multiple-dose bioequivalence study of Nevirapine 400 mg prolonged-release tablets in HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEVIRAPINE (nevirapine)

Snippet

Sponsor: Ratiopharm GmbH | Conditions: HIV-1 | Phase 1 | Status: COMPLETED